Nichole Vanells
Adult Health · East Lansing, MINPI 1952659377
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Argenx US, Inc. accounts for 80.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $3,960 and has fallen 72.5% since, to $1,091 in 2025. Among adult health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $87.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$8K
- Biogen$209
- AbbVie$185
- Genentech USA, Inc.$175
- AstraZeneca$154
- Vanda Pharmaceuticals Inc.$140
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$5,62559%
- Travel & lodging$1,37714%
- Food & beverage$2,57627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 24 | $7,679 |
| Biogen | 9 | $209 |
| AbbVie | 8 | $185 |
| Genentech USA, Inc. | 8 | $175 |
| AstraZeneca | 7 | $154 |
| Vanda Pharmaceuticals Inc. | 5 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $126 |
| Jazz Pharmaceuticals Inc. | 6 | $121 |
| UCB, Inc. | 7 | $120 |
| SK Life Science, Inc. | 6 | $100 |
| Pfizer | 4 | $87 |
| Alnylam Pharmaceuticals Inc. | 2 | $64 |
| Tanabe Pharma America, Inc. | 2 | $53 |
| Novo Nordisk | 1 | $48 |
| Hospira, Inc. | 2 | $38 |
| CSL Behring | 2 | $35 |
| Lundbeck LLC | 1 | $29 |
| Eisai Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
| Acorda Therapeutics, Inc | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$7,298
How this compares
$9,578 in reported general payments places this provider in the 95th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 65 | $587,891 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 29 | $526,063 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $496,772 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $354,046 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $7,584 |
| Pyridostigmine Bromide | 57 | $6,336 |
| Gabapentin | 95 | $1,742 |
| Sodium Chloride0.9 % Sodium Chloride | 52 | $1,118 |
| Amitriptyline Hcl | 29 | $597 |
| Pregabalin | 36 | $543 |
| Duloxetine Hcl | 17 | $448 |
| Glycopyrrolate | 21 | $440 |
| Baclofen | 14 | $220 |
| Propranolol Hcl | 11 | $179 |
| Ondansetron HclOndansetron Hcl/Pf | 51 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $126 | $587,89165 claims |
| CSL BehringPrivigen | $35 | $526,06329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 adult health providers in Michigan.
Other adult health in East Lansing
- Kasandra RischEast Lansing$7K
- Mai VangEast Lansing$6K
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.